Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

axim

HomeAXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramcoaxim

axim

Author Michael McDonaldPosted on August 10, 20180

Previous Post AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate